Walgreens is launching a “gameified” digital adherence program with HealthPrize. The program, which could start by the end of 2016, will initially be offered to patients with diabetes who take certain drugs – HealthPrize is working on enlisting a number of pharmas as sponsors. It will be web-based to start – “mobile friendly,” but no app.
IBM Watson is rolling out Watson for Oncology, the cognitive learning decision support tool incubated at Memorial Sloan Kettering Cancer Center, in 21 hospitals across China through a partnership with Hangzhou CognitiveCare.
The WSJ recently ran a great check-in on telemedicine, which is growing fast, though reimbursement and patchwork state regulations continue to pose barriers to adoption. Interesting tidbit here: Cleveland Clinic, which has worked in recent years to position itself as an international destination medical center ala Mayo or Johns Hopkins, is now working on building a “Cleveland Clinic in the cloud” via telemedicine.
Arianna Huffington is famously obsessed with sleep, so it’s fitting that she’s leaving her eponymous digital media company, the Huffington Post, to join a digital health startup working on a suite of wellness apps, many of which focus on improving sleep. Thrive Global plans a consumer play, with online sales of digital and analog wellness products (from apps to scented candles), along with a B2B pitch.
The Affordable Care Act has covered an estimated 20 million formerly uninsured Americans, but 24 million remain uninsured. They skew younger, Hispanic and Southern, being heavily concentrated in states that have not expanded Medicaid.
A Xerox survey confirms something we’ve found in our research: a disconnect in perceptions of patient empowerment – “Payers and providers are much less likely to believe patients are taking responsibility for their health than what patients perceive to be true,” underscoring a need for improved communication (and therein, an opportunity for pharma value-adds).
FDA has lost a string of cases in recent years testing its powers to prohibit pharma reps from engaging in any discussion of off-label uses of treatments with HCPs. Now BIO and PhRMA have fired a shot across the agency’s bow, releasing a set of guidelines for “truthful and non-misleading” communication of off-label info.